Senior Director, Regulatory Affairs, Pulmovant

Pulmovant is a Roivant-backed clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases.

Pulmovant’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Mosliciguat is a potential first-in-class soluble guanylate cyclase activator with a differentiated mechanism of action currently being eva…